Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
Study Details
Study Description
Brief Summary
Breast conserving surgery (BCS) is performed on patients with breast cancer to resect and completely remove the cancer while conserving as much of the surrounding healthy tissue as possible. Current methods do not allow surgeons to determine the completeness of surgical resection in real-time. This often results in the need for a second surgical procedure, or in some cases more than two surgical procedures in order to have confidence that all cancer has been removed.
This Phase 3 study will evaluate the safety and efficacy of the fluorescent imaging agent PD G 506 A for the real-time visualization of cancer during standard of care breast conserving surgery. PD G 506 A is an investigational drug which is converted in the body into a fluorescent molecule that accumulates in cancer cells. Patients receiving PD G 506 A will undergo standard of care breast conserving surgery followed by fluorescence imaging and removal of any potentially cancerous tissue left behind in the surgical cavity.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Re-operations due to positive margins following breast conserving surgery (BCS) increase poor cosmesis, complications, discomfort, stress, adjuvant delay, medical costs and risk of local recurrence. Reducing positive margin rates can be achieved through optimizing surgical procedures. This study evaluates a new method for surgeons to visualize carcinoma in real-time, both in the surgical cavity and on the margins of excised specimen(s) during the index BCS procedure.
The active ingredient of PD G 506A is aminolevulinic acid hydrochloride (ALA HCl). ALA HCl is a prodrug that is metabolized intracellularly to form the fluorescent molecule protoporphyrin IX (PpIX). The exogenous application of ALA HCl leads to a highly selective accumulation of PpIX in malignant tissues.
This Phase 3, 2-part, single-blind [pathologist(s)-blinded] randomized placebo-controlled trial study is designed to evaluate the efficacy and safety of PD G 506 A to aid in the visualization of carcinoma during BCS. The Eagle V1.2 Imaging System will be used in this trial to visualize PpIX fluorescence.
Part A is an open-label training phase of the study to optimize workflow and Part B of the study is randomized and single-blind and will serve as the pivotal portion of the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Standard of Care Arm Patients in this arm will receive the placebo orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence-guided resection will not be performed in patients in this arm. |
Drug: Placebo
Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
|
| Experimental: PD G 506 A + Fluorescence-Guided Resection Arm Patients in this arm will receive PD G 506 A orally approximately 3 hrs prior to anesthesia followed by standard of care BCS. Fluorescence imaging will be performed on tissue specimens resected prior to completion of standard of care resection. Fluorescence imaging performed after SoC BCS is complete will guide the resection of additional tissue. |
Drug: Aminolevulinic Acid Hydrochloride
PD G 506 A for oral solution (aminolevulinic acid [ALA] hydrochloride [HCl] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
Other Names:
Device: Eagle V1.2 Imaging System
Fluorescence imaging camera and associated accessories used to view and capture fluorescence and white light images and videos of the surgical cavity and excised tissue specimens during the surgical procedure.
|
Outcome Measures
Primary Outcome Measures
- Positive margin conversion rate [2 weeks]
Percentage of patients with negative-margins following fluorescence-guided resection (FGR) among patients with positive margins following standard of care (SoC)
- Diagnostic performance (Specificity) [2 weeks]
Patient-level specificity to identify residual carcinoma
- Diagnostic performance (Sensitivity) [2 weeks]
Patient-level sensitivity to identify residual carcinoma
Secondary Outcome Measures
- Orientation-level diagnostic performance [2 weeks]
Orientation-level diagnostic performance of PD G 506 A-induced fluorescence to determine the presence or absence of cancer in the surgical cavity as compared to margin histopathology.
- Positive margin conversion rate among all patients [2 weeks]
Percentage of patients with at least one histopathology-positive margin following SoC who then have ALL histopathology-negative margins following FGR, among all patients imaged.
- Patient-level diagnostic performance [2 weeks]
Patient-level sensitivity, specificity, NPV, PPV of PD G 506 A-induced fluorescence to determine the presence or absence of residual cancer
- Patient-level diagnostic performance of PD G 506 A to detect residual cancer at the end of FGR with modified patient-level definitions [2 weeks]
Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of residual cancer in the surgical cavity at the end of FGR (using modified patient-level definitions)
- Patient-level diagnostic performance of PD G 506 A to detect cancer after SoC BCS [2 weeks]
Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of cancer in the surgical cavity after SoC BCS.
- Patient-level diagnostic performance of PD G 506 A to detect cancer after SoC with modified patient-level definitions [2 weeks]
Patient-level sensitivity, specificity, PPV and NPV to determine the presence or absence of cancer in the surgical cavity after SoC (using modified patient-level definitions).
- Patient-level false negative rate of at the end of FGR [2 weeks]
Percentage of patients assessed as residual tumor negative at the end of FGR who had positive final margins on histopathology
- Patient-level false positive rate [2 weeks]
Percentage of patients in whom SOC final margins were carcinoma negative and all FL-driven shave specimens are carcinoma-negative
- Patients with carcinoma-negative margins after SoC found to have residual tumor following SoC that was identified with FL imaging [2 weeks]
Percentage of patients with histopathology-negative margins at the end of SoC who have at least one orientation that was both FL-positive and histopathology-positive among (1) patients with histopathology negative final margins after SOC and (2) all patients imaged
- Patient-level true negative rate at the end of SoC [2 weeks]
Percentage of patients with no fluorescence identified at the end of SoC in whom all final margins after SoC are histopathologically confirmed to be negative for carcinoma.
- Patient-level diagnostic performance to identify in vivo residual carcinoma after FGR [2 weeks]
Patient-level in vivo diagnostic performance of PD G 506 A-induced fluorescence to determine the presence or absence of residual cancer in the surgical cavity at the end of FGR as compared to the final margin histopathology.
- Orientation discordant fluorescence status [2 weeks]
Percentage of orientations where in vivo and ex vivo fluorescence assessments are discordant.
- Patient-level re-operation rate [1 year]
Percentage of patients receiving a 2nd surgery on the ipsilateral breast within 1 year of index BCS to remove suspected residual disease.
- Patient-level early re-operation rate [3 - 6 months]
Percentage of patients receiving an early 2nd surgery (planned or actual) on the ipsilateral breast related to positive final margins.
- Amount of tissue removed with FGR beyond SoC [2 weeks]
Weight (mg) of all tissue removed based on SoC and/of FGR
- Patient satisfaction with breast [2 weeks, 3-, 6- and 12-months]
Patient satisfaction with the cosmetic outcome of breast conserving surgery performed based on SoC in combination with PD G 506 A and the Eagle V1.2 Imaging System
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Female, 18 years or older
-
Histologically or cytologically confirmed primary breast cancer (includes invasive lobular carcinoma, invasive ductal carcinoma, inflammatory breast cancer, papillary breast cancer, adenoid cystic carcinoma of the breast, mucinous breast cancer, metaplastic breast cancer, cribriform carcinoma and ductal carcinoma in situ, alone or in combination with invasive disease)
-
Scheduled for a lumpectomy (including bilateral lumpectomy) of a breast malignancy (eligibility for breast conserving surgery/partial mastectomy based on clinical staging using TNM staging system (AJCC Cancer Staging Manual: Breast Cancer, 8th Edition70).
-
Patient must have normal organ and bone marrow function and be appropriate surgical candidate per site standard of care
-
Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) starting the day entering the study, and for the duration of the study period (until the Week 2 visit)
Exclusion Criteria:
-
Currently on (neo)adjuvant therapy to treat another cancer
-
Receiving or intended to receive neoadjuvant therapy to treat the primary breast cancer (including chemotherapy, endocrine therapy and radiotherapy)
-
Stage 4 cancer, inclusive of metastatic disease
-
Non-invasive diseases of the breast (includes lobular carcinoma in situ, phyllodes and Paget's disease of the breast)
-
Patients who have had previous surgery on the involved breast including breast surgeries, mastectomies, breast reconstructions or implants
-
Patients for whom intraoperative frozen section analysis is planned
-
Patients who have not recovered from adverse events due an investigational pharmaceutical or diagnostic agents administered more than 30 days prior to their scheduled surgical procedure
-
History of hypersensitivity to ALA HCl or porphyrins
-
Known or documented personal or family history of porphyria
-
Patient has a recording of any parameter as defined below:
-
Bilirubin: Above upper limit of normal
-
Aspartate aminotransferase (SGOT): > 2.5 X institutional upper limit of normal
-
Alanine aminotransferase ( (SGPT): > 2.5 X institutional upper limit of normal
-
Patient has serum creatinine >1.5 times institutional upper limit of normal, OR calculated creatinine clearance > 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal.
-
Uncontrolled concurrent illness, that in the opinion of the Investigator would prevent the patient from participation in the study, including but not limited to:
-
Ongoing or active infection;
-
Cardiovascular disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia).
-
Patients who have the following collagen vascular diseases:
-
Lupus
-
Scleroderma
-
Use of an investigational drug within 30 days of their scheduled surgical procedure
-
Simultaneous use of other potentially phototoxic substances (such as St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period.
-
Social or medical situations including uncontrolled psychiatric illnesses that would in the opinion of the Investigator limit compliance with study requirements (e.g. ability to travel for follow-up)
-
Patients who are pregnant or become pregnant (it is unknown if ALA HCl is teratogenic or has abortifacient effects)
-
Patients who are breast feeding (there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ALA HCl, breastfeeding should be discontinued if the mother is treated with ALA HCl)
-
Inability to consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Orlando Health, Inc. | Orlando | Florida | United States | 32806 |
| 2 | Montefiore Medical Center | Bronx | New York | United States | 10467 |
| 3 | Aurora St. Luke's Medical Centre | Milwaukee | Wisconsin | United States | 53215 |
Sponsors and Collaborators
- SBI ALApharma Canada, Inc.
Investigators
- Study Director: Ralph DaCosta, PhD, SBI ALApharma Canada
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SBI-CIP 20-002